Active Recombinant Human TRPA1 Full Length Transmembrane protein(Nanodisc)

• Cat.No.: TRPA1-2844H
• Product Overview: Recombinant Human TRPA1 Full Length Transmembrane protein(O75762), was expressed in HEK293.

Specification

• Species: Human
• Source: HEK293
• Tag: Non
• Form: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
• Bio-activity: Elisa plates were pre-coated with Flag Tag TRPA1-Nanodisc (0.2μg/per well). Serial diluted anti-Flag monoclonal antibody solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-Flag monoclonal antibody binding with TRPA1-Nanodisc is 7.433ng/ml.
• Molecular Mass: The human full length TRPA1 protein has a MW of 127.5 kDa.
• Storage: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.
• Full Length: Full L.

Gene Information

• Gene Name: TRPA1 transient receptor potential cation channel, subfamily A, member 1 [ Homo sapiens ]
• Official Symbol: TRPA1
• Synonyms: TRPA1; transient receptor potential cation channel, subfamily A, member 1; ANKTM1, ankyrin like with transmembrane domains 1; transient receptor potential cation channel subfamily A member 1; transformation-sensitive protein p120; ankyrin-like with transmembrane domains 1; ankyrin-like with transmembrane domains protein 1; ANKTM1
• Gene ID: 8989
• mRNA Refseq: NM_007332
• Protein Refseq: NP_015628
• MIM: 604775
• UniProt ID: O75762

Reviews

10/02/2024

TRPA1-2844H

This protein seems to behave acceptably for against one pAb in my preclinical work thus far.